

- Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer* 1998;83:1664–1678.
- Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med* 2005;353:2135–2147.
- Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* 2009;457:599–602.
- Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. *N Engl J Med* 2010;363:2191–2199.
- Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949–954.
- Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. *J Clin Oncol* 2006;24:4340–4346.
- Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol* 2011;29:1239–1246.
- Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. *Clin Cancer Res* 2012;18:3242–3249.
- Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 2013;499:214–218.
- Pleasant ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature* 2010;463:191–196.
- Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. *Nat Genet* 2012;44:1006–1014.
- Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. *Cell* 2012;150:251–263.
- Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. *Science* 2013;339:957–959.
- Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. *Science* 2013;339:959–961.
- Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. *Nature* 2007;445:851–857.
- Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. *JAMA* 2011;305:2327–2334.
- Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. *PLoS Med* 2008;5:e120.
- Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* 2004;116:855–867.
- Madhupantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. *Pigment Cell Melanoma Res* 2009;22:400–419.
- Kwon LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. *Clin Cancer Res* 2013;19:5310–5319.
- Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. *Clin Cancer Res* 2013;19:5320–5328.
- Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. *Nat Genet* 2003;33:19–20.
- Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAF600-associated senescence-like cell cycle arrest of human naevi. *Nature* 2005;436:720–724.
- Mooi WJ, Peeper DS. Oncogene-induced cell senescence—halting on the road to cancer. *N Engl J Med* 2006;355:1037–1046.
- Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. *J Am Acad Dermatol* 2011;65:S17–25.e3.
- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. *CA Cancer J Clin* 2010;60:277–300.
- Mack TM, Floderus B. Malignant melanoma risk by nativity, place of residence at diagnosis, and age at migration. *Cancer Causes Control* 1991;2:401–411.
- Bulliard JL, Cox B. Cutaneous malignant melanoma in New Zealand: trends by anatomical site, 1969–1993. *Int J Epidemiol* 2000;29:416–423.
- Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. *Oncologist* 2007;12:20–37.
- Elder DE, Xu X. The approach to the patient with a difficult melanocytic lesion. *Pathology* 2004;36:428–434.
- Shaw HM, Thompson JF. Prognosis in children with melanoma. *N Z Med J* 2001;114:75.
- Gilchrist BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. *N Engl J Med* 1999;340:1341–1348.
- Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and melanoma: a review. *J Am Acad Dermatol* 2001;44:837–846.
- Zaidi MR, Davis S, Noonan FP, et al. Interferon-gamma links ultraviolet radiation to melanomagenesis in mice. *Nature* 2011;469:548–553.
- Elwood JM. Melanoma and sun exposure. *Semin Oncol* 1996;23:650–666.
- Garibyan L, Fisher DE. How sunlight causes melanoma. *Curr Oncol Rep* 2010;12:319–326.
- Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. *Int J Cancer* 2011;128:2425–2435.
- Badenas C, Aguilera P, Puig-Butlle JA, et al. Genetic counseling in melanoma. *Dermatol Ther* 2012;25:397–402.
- Hussussian CJ, Struwing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. *Nat Genet* 1994;8:15–21.
- Bartsch DK, Langer P, Habbe N, et al. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. *Clin Gen* 2010;77:333–341.
- Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature* 2011;480:94–98.
- Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. *Nature* 2011;480:99–103.
- Curiel-Lewandrowski C, Speetzen LS, Crammer L, et al. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. *Arch Dermatol* 2011;147:248–250.
- Slingluff CL Jr, Reintgen DS, Vollmer RT, et al. Malignant melanoma arising during pregnancy. A study of 100 patients. *Ann Surg* 1990;211:552–557, discussion 558–559.
- Slingluff CL Jr, Reintgen D. Malignant melanoma and the prognostic implications of pregnancy, oral contraceptives, and exogenous hormones. *Semin Surg Oncol* 1993;9:228–231.
- MacKie RM. Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. *Curr Opin Oncol* 1999;11:129–131.
- Slingluff CL Jr, Dodge RK, Stanley WE, et al. The annual risk of melanoma progression. Implications for the concept of cure. *Cancer* 1992;70:1917–1927.
- Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. *J Clin Oncol* 2011;29:257–263.
- van der Pols JC, Williams GM, Pandeya N, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. *Cancer Epidemiol Biomarkers Prev* 2006;15:2546–2548.
- Autier P, Severi G, Dore JF. Beta-carotene and sunscreen use. *Lancet* 1999;354:2163–2164.
- Mitra D, Luo X, Morgan A, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. *Nature* 2012;491:449–453.
- Koh HK, Miller DR, Geller AC, et al. Who discovers melanoma? Patterns from a population-based survey. *J Am Acad Dermatol* 1992;26:914–919.
- Berwick M, Begg CB, Fine JA, et al. Screening for cutaneous melanoma by skin self-examination. *J Natl Cancer Inst* 1996;88:17–23.
- Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. *Cancer* 2012;118:5395–5402.
- Clark WH Jr. The dysplastic nevus syndrome. *Arch Dermatol* 1988;124:1207–1210.
- Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. *N Engl J Med* 2003;349:2233–2240.
- Malvey J, Puig S, Argenziano G, et al. Dermoscopy report: proposal for standardization. Results of a consensus meeting of the International Dermoscopy Society. *J Am Acad Dermatol* 2007;57:84–95.
- NIH Consensus Conference. Diagnosis and treatment of early melanoma. *JAMA* 1992;268:1314–1319.
- Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). *Clin Cancer Res* 2013;19:4868–4878.
- Garraway LA, Baselga J. Whole-genome sequencing and cancer therapy: is too much ever enough? *Cancer Discov* 2012;2:766–768.
- Grob JJ, Bonerandi JJ. The “ugly duckling” sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. *Arch Dermatol* 1998;134:103–104.
- Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. *Br J Dermatol* 2006;155:771–777.
- Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. *Br J Dermatol* 1987;116:303–310.
- King R, Page RN, Googe PB, et al. Lentiginous melanoma: a histologic pattern of melanoma to be distinguished from lentiginous nevus. *Mod Pathol* 2005;18:1397–1401.
- Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. *Cancer* 2010;116:4130–4138.
- Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). *Cancer* 1971;28:914–936.
- George E, McClain SE, Slingluff CL, et al. Subclassification of desmoplastic melanoma: pure and mixed variants have significantly different capacities for lymph node metastasis. *J Cutan Pathol* 2009;36:425–432.
- Hawkins WC, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. *Ann Surg Oncol* 2005;12:207–213.
- Posther KE, Selim MA, Mosca PJ, et al. Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. *Ann Surg Oncol* 2006;13:728–739.
- Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. *Cancer* 1998;83:1128–1135.

71. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. *Cancer* 2006;106:900–906.
72. Han D, Zager JS, Yu D, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? *Ann Surg Oncol* 2013;20:2345–2351.
73. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. *Ann Surg* 1970;172:902–908.
74. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009;27:6199–6206.
75. Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. *Cancer Res* 1969;29:705–727.
76. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol* 2001;19:3622–3634.
77. Day CL Jr, Lew RA, Mihm MC Jr, et al. The natural break points for primary-tumor thickness in clinical Stage I melanoma. *N Engl J Med* 1981;305:1155.
78. Slingluff CL Jr, Vollmer RT, Reintgen DS, et al. Lethal “thin” malignant melanoma. Identifying patients at risk. *Ann Surg* 1988;208:150–161.
79. Slingluff CL Jr, Vollmer R, Seigler HF. Acral melanoma: a review of 185 patients with identification of prognostic variables. *J Surg Oncol* 1990;45:91–98.
80. Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. *Ann Surg* 2006;244:1012–1017.
81. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. *Cancer* 2007;109:100–108.
82. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. *Cancer* 2003;97:1488–1498.
83. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. *J Clin Oncol* 2005;23:8048–8056.
84. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. *J Clin Oncol* 2004;22:3668–3676.
85. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. *J Clin Oncol* 2010;28:2452–2459.
86. Balch CM, Gershenwald JE, Soong SJ, et al. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. *J Surg Oncol* 2011;104:379–385.
87. Silva E. Adjunct primer for the use of national comprehensive cancer network guidelines for the surgical management of cutaneous malignant melanoma patients. *World J Surg Oncol* 2012;10:54.
88. Terhune MH, Swanson N, Johnson TM. Use of chest radiography in the initial evaluation of patients with localized melanoma. *Arch Dermatol* 1998;134:569–572.
89. Vermeeren L, van der Ent FW, Hulsewe KW. Is there an indication for routine chest X-ray in initial staging of melanoma? *J Surg Res* 2011;166:114–119.
90. Sawyer A, McGoldrick RB, Mackey SP, et al. Does staging computerized tomography change management in thick malignant melanoma? *J Plast Reconstr Aesthet Surg* 2009;62:453–456.
91. Constantinidou A, Hofman M, O’Doherty M, et al. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. *Melanoma Res* 2008;18:56–60.
92. Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. *Cancer* 2007;110:1107–1114.
93. Glaspy JA, Hawkins R, Hoh CK, et al. Use of positron emission tomography in oncology. *Oncology (Williston Park)* 1993;7:41–46, 49–50, discussion 50–52, 55.
94. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. *Cancer* 2005;104:570–579.
95. Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. *Arch Surg* 2006;141:284–288.
96. Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. *Ann Surg Oncol* 2007;14:2133–2140.
97. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. *Arch Surg* 1991;126:438–441.
98. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. *N Engl J Med* 1988;318:1159–1162.
99. Cascinelli N, Santinami M, Maurichi A, et al. World Health Organization experience in the treatment of melanoma. *Surg Clin North Am* 2003;83:405–416.
100. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). *Cancer* 2003;97:1941–1946.
101. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. *Cancer* 2000;89:1495–1501.
102. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. *Ann Surg Oncol* 2001;8:101–108.
103. Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. *N Engl J Med* 2004;350:757–766.
104. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. *J Clin Oncol* 1988;6:163–172.
105. Slingluff CL Jr, Stidham KR, Ricci WM, et al. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. *Ann Surg* 1994;219:120–130.
106. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. *N Engl J Med* 1977;297:627–630.
107. Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. *Ann Surg Oncol* 2000;7:87–97.
108. Cabanas RM. An approach for the treatment of penile carcinoma. *Cancer* 1977;39:456–466.
109. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch Surg* 1992;127:392–399.
110. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. *Ann Surg* 1999;230:453–463, discussion 463–465.
111. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. *J Clin Oncol* 1998;16:2253–2260.
112. Harlow SP, Krag DN, Ashikaga T, et al. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. *Melanoma Res* 2001;11:45–55.
113. Roozendaal GK, de Vries JD, van Poll D, et al. Sentinel nodes outside lymph node basins in patients with melanoma. *Br J Surg* 2001;88:305–308.
114. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. *J Clin Oncol* 1999;17:976–983.
115. Gershenwald JE, Mansfield PF, Lee JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. *Ann Surg Oncol* 2000;7:160–165.
116. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. *Ann Surg* 2005;242:302–311, discussion 311–313.
117. Vermeeren L, Valdes Olmos RA, Klop WM, et al. A portable gamma-camera for intraoperative detection of sentinel nodes in the head and neck region. *J Nucl Med* 2010;51:700–703.
118. Testori A, De Salvo GL, Montesco MC, et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). *Ann Surg Oncol* 2009;16:2018–2027.
119. Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. *Ann Surg* 2003;238:538–549, discussion 549–550.
120. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. *N Engl J Med* 2006;355:1307–1317.
121. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. *N Engl J Med* 2014;370:599–609.
122. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). *Ann Surg Oncol* 2010;17:3324–3329.
123. Kilbridge KL, Weeks JC, Sober AJ, et al. Patient preferences for adjuvant interferon alfa-2b treatment. *J Clin Oncol* 2001;19:812–823.
124. Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. *Ann Surg Oncol* 2003;10:403–407.
125. Gannon CJ, Rousseau DL Jr, Ross MI, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. *Cancer* 2006;107:2647–2652.
126. Abramova L, Slingluff CL Jr, Patterson JW. Problems in the interpretation of apparent “radial growth phase” malignant melanomas that metastasize. *J Cutan Pathol* 2002;29:407–414.
127. Slingluff CL Jr, Seigler HF. “Thin” malignant melanoma: risk factors and clinical management. *Ann Plast Surg* 1992;28:89–94.
128. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma V.2.2014. © National Comprehensive Cancer Network, Inc. 2014. All rights reserved. Accessed April 22, 2014.
129. Wong SL, Balch CM, Hurler P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. *J Clin Oncol* 2012;30:2912–2918.

130. Orfanoti G, Mennie JC, Fairbairn N, et al. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland. *J Plast Reconstr Aesthet Surg* 2012;65:1216–1219.
131. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. *Ann Surg Oncol* 1998;5:322–328.
132. Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. *J Am Acad Dermatol* 2000;43:477–482.
133. Spenny ML, Walford J, Werchniak AE, et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. *Cutis* 2007;79:149–152.
134. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. *Br J Dermatol* 2006;155:653–656.
135. van Meurs T, van Doorn R, Kirtschig G. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. *Dermatol Surg* 2007;33:623–626, discussion 626–627.
136. Somani N, Martinka M, Crawford RI, et al. Treatment of atypical nevi with imiquimod 5% cream. *Arch Dermatol* 2007;143:379–385.
137. Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. *Head Neck* 2003;25:423–428.
138. Slingluff CL Jr, Vollmer RF, Seigler HF. Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. *Surgery* 1990;107:1–9.
139. Irvin WP Jr, Bliss SA, Rice LW, et al. Malignant melanoma of the vagina and locoregional control: radical surgery revisited. *Gynecol Oncol* 1998;71:476–480.
140. Abramova L, Parekh J, Irvin WP Jr, et al. Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review. *Ann Surg Oncol* 2002;9:840–846.
141. Tien HY, McMasters KM, Edwards MJ, et al. Sentinel lymph node metastasis in anal melanoma: a case report. *Int J Gastrointest Cancer* 2002;32:53–56.
142. Hazard LJ, Sause WT, Noyes RD. Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. *Int J Radiat Oncol Biol Phys* 2002;52:796–800.
143. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. *JAMA* 1995;274:1703–1705.
144. Mooney MM, Mettlin C, Michalek AM, et al. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. *Cancer* 1997;80:1052–1064.
145. Reintgen DS, Cox C, Slingluff CL Jr, et al. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. *Ann Plast Surg* 1992;28:45–49.
146. Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. *J Am Coll Surg* 1999;189:195–204.
147. Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? *Ann Surg* 2003;238:743–747.
148. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. *J Clin Oncol* 1997;15:1039–1051.
149. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. *Melanoma Res* 2008;18:405–411.
150. Damian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. *Australas J Dermatol* 2009;50:266–271.
151. McArthur GA, Ribas A. Targeting oncogenic drivers and the immune system in melanoma. *J Clin Oncol* 2013;31:499–506.
152. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. *J Clin Oncol* 2006;24:4196–4201.
153. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. *Ann Surg* 2007;245:591–596.
154. Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. *Lancet Oncol* 2003;4:359–364.
155. Morton DL. Cancer immunotherapy: an overview. *Semin Oncol* 1974;1:297–310.
156. Andtbacka RH, Collichio FA, Amatruda T, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. *J Clin Oncol* 2013;31:Abstr LBA9008.
157. Jahanshahi P, Nasr N, Unger K, et al. Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. *Front Oncol* 2012;2:167.
158. Slingluff CL Jr, Vollmer R, Seigler HF. Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. *J Surg Oncol* 1988;39:139–147.
159. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. *J Clin Oncol* 2001;19:2851–2855.
160. Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. *Ann Surg Oncol* 2008;15:1566–1576.
161. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. *Mod Pathol* 2004;17:747–755.
162. Wrightson WR, Wong SL, Edwards MJ, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of nonsentinel nodes following completion lymphadenectomy for melanoma. *J Surg Res* 2001;98:47–51.
163. McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. *Ann Surg Oncol* 2002;9:137–141.
164. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. *Ann Surg Oncol* 2006;13:809–816.
165. Faries MB, Morton DL. Surgery and sentinel lymph node biopsy. *Semin Oncol* 2007;34:498–508.
166. Spratt J. Groin dissection. *J Surg Oncol* 2000;73:243–262.
167. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. *Cancer Res* 1971;31:830–833.
168. Katz HR. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. *Int J Radiat Oncol Biol Phys* 1981;7:907–911.
169. Ballo MT, Ross MI, Cormier JN, et al. Combined-modality therapy for patients with regional nodal metastases from melanoma. *Int J Radiat Oncol Biol Phys* 2006;64:106–113.
170. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. *Arch Surg* 1989;124:1051–1055.
171. Chang DT, Amdur RJ, Morris CG, et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. *Int J Radiat Oncol Biol Phys* 2006;66:1051–1055.
172. Stevens G, Thompson JF, Firth I, et al. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. *Cancer* 2000;88:88–94.
173. Agrawal S, Kane JM 3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. *Cancer* 2009;115:5836–5844.
174. Burmeister BH, Mark Smithers B, Burmeister E, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma—Trans Tasman Radiation Oncology Group (TROG) Study 96.06. *Radiother Oncol* 2006;81:136–142.
175. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. *Lancet Oncol* 2012;13:589–597.
176. Mocellin S, Lens MB, Pasquali S, et al. Interferon alpha for the adjuvant treatment of cutaneous melanoma. *Cochrane Database Syst Rev* 2013;6:CD008955.
177. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. *J Clin Oncol* 1996;14:7–17.
178. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 1996;14:2666–2673.
179. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. *Clin Cancer Res* 2004;10:1670–1677.
180. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. *J Clin Oncol* 1995;13:2776–2783.
181. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. *Lancet* 2001;358:866–869.
182. Cameron DA, Comblett MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma—the Scottish study. *Br J Cancer* 2001;84:1146–1149.
183. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. *J Clin Oncol* 2004;22:53–61.
184. Hauschild A, Weichenthal M, Rass K, et al. Efficacy of low-dose interferon (alpha)2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. *J Clin Oncol* 2010;28:841–846.
185. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon (alpha)2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. *Ann Oncol* 2008;19:1195–1201.
186. Eggermont AM, Suci S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. *Lancet* 2005;366:1189–1196.

187. Ascierto PA, Chiarion-Sileni V, Muggiano A, et al. Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. *J Chemother* 2013;1973947813Y0000000154.
188. Agarwala SS, Lee SJ, Flaherty LE, et al. Randomized phase III trial of high-dose interferon alfa-2b (HD1) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). *J Clin Oncol* 2011;29:Abstr 8505.
189. Eggermont AM, Suciú S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. *Lancet* 2008;372:117–126.
190. Eggermont AM, Suciú S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. *J Clin Oncol* 2012;30:3810–3818.
191. Flaherty LE, Othus M, Atkins MB, et al. Phase III trial of high dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high risk melanoma (SWOG S0008): an intergroup trial of CALGB, COG, EOCG and SWOG. *J Clin Oncol* 2012;30:Abstr 8504.
192. Lawson DH, Lee SJ, Tarhini AA, et al. E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. *J Clin Oncol* 2010;28:Abstr 8504.
193. Hailemichael Y, Dai Z, Jaffarzar N, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. *Nat Med* 2013;19:465–472.
194. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *J Clin Invest* 2005;115:739–746.
195. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–723.
196. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517–2526.
197. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. *J Clin Oncol* 2006;24:3164–3171.
198. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. *J Clin Oncol* 2010;28:3042–3047.
199. Dancey A, Rayatt S, Courthold J, et al. Views of UK melanoma patients on routine follow-up care. *Br J Plast Surg* 2005;58:245–250.
200. Pflugfelder A, Kochs C, Blum A, et al. Malignant melanoma S3-guideline “diagnosis, therapy and follow-up of melanoma.” *J Dtsch Dermatol Ges* 2013;11:1–116, 1–126.
201. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. *Ann Surg* 1990;212:173–177.
202. Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. *J Clin Oncol* 2000;18:3782–3793.
203. Swetter SM, Carroll LA, Johnson DL, et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. *Ann Surg Oncol* 2002;9:646–653.
204. Sortini D, Feo CV, Carcoforo P, et al. Thoracoscopic localization techniques for patients with solitary pulmonary nodule and history of malignancy. *Ann Thorac Surg* 2005;79:258–262, discussion 262.
205. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell* 2010;140:209–221.
206. Poulidakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. *Nature* 2010;464:427–430.
207. Halaban R, Zhang W, Bacchiocchi A, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. *Pigment Cell Melanoma Res* 2010;23:190–200.
208. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *N Engl J Med* 2012;366:207–215.
209. Berger AC, Buell JF, Venzon D, et al. Management of symptomatic malignant melanoma of the gastrointestinal tract. *Ann Surg Oncol* 1999;6:155–160.
210. Tagawa ST, Cheung E, Banta W, et al. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. *Cancer* 2006;106:1353–1357.
211. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. *J Clin Oncol* 2008;26:527–534.
212. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252–264.
213. Margolin KA, Hamid O, Weber JS, et al. Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience. *J Clin Oncol* 2013;31:Abstr 9041.
214. Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. *J Clin Oncol* 2013;31:Abstr CRA9007.
215. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. *J Clin Oncol* 2005;23:8968–8977.
216. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol* 2013;31:616–622.
217. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Clin Cancer Res* 2010;16:1042–1048.
218. Ribas A, Hauschild A, Kefford R. Reply to K.S. Wilson et al. *J Clin Oncol* 2013;31:2836–2837.
219. Ribas A, Glaspy JA, Lee Y, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. *J Immunother* 2004;27:354–367.
220. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? *Clin Cancer Res* 2009;15:7116–7118.
221. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009;15:7412–7420.
222. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985;313:1485–1492.
223. Lotze MT, Chang AE, Seipp CA, et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. *JAMA* 1986;256:3117–3124.
224. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 1999;17:2105–2116.
225. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008;14:5610–5618.
226. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma [see comments]. *Nat Med* 1998;4:321–327.
227. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N Engl J Med* 2011;364:2119–2127.
228. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. *Nat Rev Clin Oncol* 2011;8:426–433.
229. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011;364:2507–2516.
230. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N Engl J Med* 2012;366:707–714.
231. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. *J Clin Oncol* 2012;30:316–321.
232. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012;380:358–365.
233. Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). *J Clin Oncol* 2013;31:Abstract 9013.
234. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 2006;439:358–362.
235. von Euiw E, Atefi M, Attar N, et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. *Mol Cancer* 2012;11:22.
236. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med* 2012;367(2):107–114.
237. Poulidakos PI, Persaud Y, Janakiramam M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). *Nature* 2011;480:387–390.
238. Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. *Nat Commun* 2012;3:724.
239. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature* 2010;468:973–977.
240. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. *J Clin Oncol* 2011;29:3085–3096.
241. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. *J Clin Oncol* 2013;31:1767–1774.
242. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature* 2010;468:968–972.

243. Shi H, Kong X, Ribas A, et al. Combinatorial treatments that overcome PDGFR(beta)-driven resistance of melanoma cells to V600E-BRAF inhibition. *Cancer Res* 2011;71:5067–5074.
244. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. *Cancer Cell* 2010;18:683–695.
245. Shi H, Hong A, Kong X, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. *Cancer Discov* 2014;4:69–79.
246. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov* 2014;4:80–93.
247. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. *Cancer Discov* 2014;4:94–109.
248. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012;367:1694–1703.
249. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. *J Clin Oncol* 2013;31:482–489.
250. Seghers AC, Wilgenhof S, Lebbe C, et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. *Melanoma Res* 2012;22:466–472.
251. Comis RL. DTIC (NSC-45388) in malignant melanoma: a perspective. *Cancer Treat Rep* 1976;60:165–176.
252. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRC 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. *Cancer Res* 1987;47:5846–5852.
253. Patel M, McCully C, Godwin K, et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. *J Neurooncol* 2003;61:203–207.
254. Margolin K, Atkins B, Thompson A, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. *J Cancer Res Clin Oncol* 2002;128:214–218.
255. Patel PM, Suci S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). *Eur J Cancer* 2011;47:1476–1483.
256. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. *Cancer* 1990;66:1873–1878.
257. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. *J Clin Oncol* 1999;17:2745–2751.
258. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol* 2008;26:5748–5754.
259. Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. *J Clin Oncol* 2013;31:373–379.
260. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. *J Clin Oncol* 2009;27:2823–2830.
261. Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. *J Clin Oncol* 2007;25:5426–5434.
262. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin, and interferon- α -2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. *J Clin Oncol* 2005;23:6747–6755.
263. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012;366:2455–2465.
264. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–2454.
265. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 2013;369:134–144.
266. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol* 2014;32:1020–1030.
267. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2013;369:122–133.
268. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. *Nat Rev Clin Oncol* 2011;8:577–585.
269. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin Cancer Res* 2011;17:4550–4557.
270. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. *Nat Rev Immunol* 2012;12:269–281.
271. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N Engl J Med* 1988;319:1676–1680.
272. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 [see comments]. *J Natl Cancer Inst* 1994;86:1159–1166.
273. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science* 2002;298:850–854.
274. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006;314:126–129.
275. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood* 2009;114:535–546.
276. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat Med* 2013;19:747–752.
277. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *J Clin Oncol* 2011;29:917–924.
278. Carella RJ, Gelber R, Hendrickson F, et al. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. *Cancer* 1980;45:679–683.
279. Ellerhorst J, Strom E, Nardone E, et al. Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases. *Int J Radiat Oncol Biol Phys* 2001;49:93–97.
280. Mornex F, Thomas L, Mohr P, et al. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. *Cancer Radiotherp* 2003;7:1–8.
281. Yu C, Chen JC, Apuzzo ML, et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. *Int J Radiat Oncol Biol Phys* 2002;52:1277–1287.
282. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet* 2004;363:1665–1672.
283. Manon R, O'Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). *J Clin Oncol* 2005;23:8870–8876.
284. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. *Lancet* 2005;366:643–648.
285. Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic body radiation therapy in multiple organ sites. *J Clin Oncol* 2007;25:947–952.
286. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. *Cancer Res* 2003;63:8466–8475.
287. Perez CA, Fu A, Onishko H, et al. Radiation induces an antitumor immune response to mouse melanoma. *Int J Radiat Biol* 2009;85:1126–1136.
288. Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. *J Immunother* 2010;33:1–7.
289. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. *N Engl J Med* 2012;366:925–931.
290. Starnell EF, Wolchok JD, Gnjatic S, et al. The abscopal effect associated with a systemic anti-melanoma immune response. *Int J Radiat Oncol Biol Phys* 2013;85:293–295.